Early access
Sign in
Not yet taking people in Hong KongNo phase

Tests a new outpatient care model for people with heart failure

Studies whether a new clinic-based follow-up service helps adults with heart failure after hospital discharge.

Key facts

Who runs it
Chinese University of Hong Kong
Where
Shatin, Hong KongSee the site
Trial code
Registry title
Ambulatory Heart Failure Service Model Study
Status
Not yet recruiting
People taking part
500 people, planned
Started
Oct 2022
Expected to end
Jan 2028
Type of study
Observational
Treatments tested
  • Standard care
Record updated
27 September 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure who were in hospital for it and can move about outside hospital. It tests a new outpatient service model.

Age
18 years or older
Sex
All sexes can join
Disease stage
Heart failure with breathlessness and at least 2 signs of fluid build-up. NT-proBNP of at least 300 pg/mL, or at least 900 pg/mL with atrial fibrillation (AF). A heart failure hospital stay needing at least 40 mg of i.v. furosemide (or an equivalent i.v. loop diuretic).
Earlier treatment
A heart failure hospital stay that needed at least a single 40 mg dose of i.v. furosemide (or an equivalent i.v. loop diuretic).
Biomarker or test result
NT-proBNP of at least 300 pg/mL (at least 900 pg/mL if the person has AF)

Main reasons for not taking part

  • Cardiogenic shock that needed inotropic drugs
  • Heart pump implant such as LVAD
  • Life expectancy under 1 year because of other serious illness, such as metastatic cancer or end-stage COPD
  • Severe uncorrected heart valve disease planned for surgery or intervention during the study
  • End stage renal failure, eGFR below 15 mL/min/1.73m2, or dialysis

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Dyspnoea (exertional or at rest) and 2 of the following signs:
  • Congestion on chest X-ray
  • Rales on chest auscultation
  • Clinically relevant oedema (e.g. ≥1+ on a 0 to 3+ scale)
  • Elevated jugular venous pressure
  • NT-proBNP ≥300 pg/mL (Patients with AF: NT-proBNP ≥900 pg/mL)
  • Heart failure hospitalization that requires the treatment of a minimum single dose of 40 mg of i.v. furosemide (or equivalent i.v loop diuretics)
  • Ambulatory patients

Who cannot take part

  • Cardiac mechanical support implantation like LVAD
  • Life expectancy less than 1 year due to underlying significant comorbidities like metastatic cancer or end-stage COPD
  • Haemodynamically severe uncorrected primary cardiac valvular disease planned for surgery or intervention during the course of the study
  • End stage renal failure or eGFR <15 mL/min/1.73m2 as measured during index hospitalization or requiring dialysis
  • Cardiogenic shock required inotropics

Where in Hong Kong

  • The Chinese University of Hong KongShatin, Hong KongContact: Daniel XuNot yet recruiting

About the trial

What the trial wants to find out

The aim of the study is to assess the efficacy of this new ambulatory service model in reducing heart failure hospitalization (HHF), improving clinical as well as functional outcomes of post-discharge patients with Heart Failure of reduced ejection fraction (HFrEF) and Heart failure with preserved Ejection Fraction (HFpEF).

The group in the trial

  • REDUCE

    Standard care

    Treatment: Standard care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Reduction of Decompensation and Unnecessary Cardiac Failure Emergency Admissions: Ambulatory Heart Failure Service Model
Plain-language title
Tests a new outpatient care model for people with heart failureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 September 2022